Broadlane to Supply Cepheid's Molecular Dx Line to US Medical Facilities

Nov 29, 2007

NEW YORK (GenomeWeb News) – Healthcare supply company Broadlane will sell Cepheid’s molecular diagnostics instruments, reagents, and services to its customers, which include more than 20,000 healthcare facilities in the US, Cepheid said today.

Broadlane’s client base includes acute care hospitals, ambulatory care facilities, and physician’s offices, Cepheid said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Dual Listings Sought

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

Allocating the Grant Pie

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

More Proposed for NSF

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

This Week in PNAS

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.

Main menu